Concise review: Neutral endopeptidase (CD10): A multifaceted environment actor in stem cells, physiological mechanisms, and cancer

Stem Cells

Volumn 29, Issue 3, 2011, Pages 389-396

  Maguer Satta, Veronique ^a,b,c   Besançon, Roger ^a,b,c,d   Bachelard Cascales, Elodie ^a,b,c  

^a UNIVERSITÉ DE LYON   (France)

^b CENTRE LÉON BÉRARD   (France)

^c IFR62   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

Cancer; CD10 enzyme; Microenvironment; Signaling; Stem cells

Indexed keywords

MEMBRANE METALLOENDOPEPTIDASE; TUMOR MARKER;

BREAST EPITHELIUM; CANCER SURVIVAL; CARCINOGENESIS; ENZYME ACTIVITY; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; IMMUNE SYSTEM; MICROENVIRONMENT; MOLECULAR DIAGNOSIS; NERVOUS SYSTEM FUNCTION; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STEM CELL;

ANIMALS; HUMANS; IMMUNE SYSTEM; MAMMARY GLANDS, HUMAN; NEOPLASMS; NEPRILYSIN; NERVOUS SYSTEM; NERVOUS SYSTEM PHYSIOLOGICAL PHENOMENA; STEM CELLS; TUMOR MICROENVIRONMENT;

EID: 79953012136     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.592     Document Type: Review

References (74)

1. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 2004;16:558-564. (Pubitemid 39201241)
2. Roques BP, Noble F, Dauge V et al. Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 1993;45:87-146. (Pubitemid 23108243)
3. Turner AJ, Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and Pex. FASEB J 1997;11:355-364. (Pubitemid 27193940)
4. Malfroy B, Kuang WJ, Seeburg PH et al. Molecular cloning and amino acid sequence of human enkephalinase (neutral endopeptidase). FEBS Lett 1988;229:206-210. (Pubitemid 18058767)
5. Barker PE, Shipp MA, D'Adamio L et al. The common acute lymphoblastic leukemia antigen gene maps to chromosomal region 3 (q21-q27). J Immunol 1989;142:283-287. (Pubitemid 19034755)
6. Ishimaru F, Potter NS, Shipp MA. Phorbol ester-mediated regulation of CD10/neutral endopeptidase transcripts in acute lymphoblastic leukemias. Exp Hematol 1996;24:43-48. (Pubitemid 26041773)
7. Sumitomo M, Shen R, Nanus DM. Involvement of neutral endopeptidase in neoplastic progression. Biochim Biophys Acta 2005;1751:52-59. (Pubitemid 41033294)
8. Zheng R, Iwase A, Shen R et al. Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase. Oncogene 2006;25:5942-5952. (Pubitemid 44477288)
9. Goodman OB Jr, Febbraio M, Simantov R et al. Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2. J Biol Chem 2006;281:33597-33605. (Pubitemid 46036740)
10. D'Adamio L, Shipp MA, Masteller EL et al. Organization of the gene encoding common acute lymphoblastic leukemia antigen (neutral endopeptidase 24.11): Multiple miniexons and separate 5′ untranslated regions. Proc Natl Acad Sci USA 1989;86:7103-7107. (Pubitemid 19240873)
11. Erdos EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989;3:145-151.
12. Oefner C, D'Arcy A, Hennig M et al. Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon. J Mol Biol 2000;296:341-349.
13. Marie-Claire C, Tiraboschi G, Ruffet E et al. Exploration of the S(′)(1) subsite of neprilysin: A joined molecular modeling and site-directed mutagenesis study. Proteins 2000;39:365-371.
14. David C, Bischoff L, Meudal H et al. Investigation of subsite preferences in aminopeptidase A (EC 3.4.11.7) led to the design of the first highly potent and selective inhibitors of this enzyme. J Med Chem 1999;42:5197-5211. (Pubitemid 30020271)
15. Bene MC. Immunophenotyping of acute leukaemias. Immunol Lett 2005;98:9-21. (Pubitemid 40409814)
16. Imai K, Kanzaki H, Fujiwara H et al. Expression of aminopeptidase N and neutral endopeptidase on the endometrial stromal cells in endometriosis and adenomyosis. Hum Reprod 1992;7:1326-1328.
17. Metzgar RS, Borowitz MJ, Jones NH et al. Distribution of common acute lymphoblastic leukemia antigen in nonhematopoietic tissues. J Exp Med 1981;154:1249-1254. (Pubitemid 11023113)
18. Song J, Aumuller G, Xiao F et al. Cell specific expression of CD10/neutral endopeptidase 24.11 gene in human prostatic tissue and cells. Prostate 2004;58:394-405. (Pubitemid 38295033)
19. Loke SL, Leung CY, Chiu KY et al. Localisation of CD10 to biliary canaliculi by immunoelectron microscopical examination. J Clin Pathol 1990;43:654-656. (Pubitemid 20228926)
20. Sato Y, Itoh F, Hinoda Y et al. Expression of CD10/neutral endopeptidase in normal and malignant tissues of the human stomach and colon. J Gastroenterol 1996;31:12-17. (Pubitemid 26048466)
21. Helisalmi S, Hiltunen M, Vepsalainen S et al. Polymorphisms in neprilysin gene affect the risk of Alzheimer's disease in Finnish patients. J Neurol Neurosurg Psychiatry 2004;75:1746-1748. (Pubitemid 39611478)
22. Iijima-Ando K, Hearn SA, Granger L et al. Overexpression of neprilysin reduces Alzheimer amyloid-beta42 (Abeta42)-induced neuron loss and intraneuronal Abeta42 deposits but causes a reduction in cAMP-responsive element-binding protein-mediated transcription, age-dependent axon pathology, and premature death in Drosophila. J Biol Chem 2008;283:19066-19076.
23. Shipp MA, Stefano GB, Switzer SN et al. CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation. Blood 1991;78:1834-1841.
24. Lu B, Gerard NP, Kolakowski LF Jr, et al. Neutral endopeptidase modulation of septic shock. J Exp Med 1995;181:2271-2275.
25. Karlsson C, Brantsing C, Egell S et al. Notch1, Jagged1, and HES5 are abundantly expressed in osteoarthritis. Cells Tissues Organs 2008;188:287-298.
26. Velazquez EF, Yancovitz M, Pavlick A et al. Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma. J Transl Med 2007;5:2.
27. Atherton AJ, Anbazhagan R, Monaghan P et al. Immunolocalisation of cell surface peptidases in the developing human breast. Differentiation 1994;56:101-106. (Pubitemid 24102012)
28. Sunday ME, Hua J, Torday JS et al. CD10/neutral endopeptidase 24.11 in developing human fetal lung. Patterns of expression and modulation of peptide-mediated proliferation. J Clin Invest 1992;90:2517-2525. (Pubitemid 23010073)
29. Weil M, Itin A, Keshet E. A role for mesenchyme-derived tachykinins in tooth and mammary gland morphogenesis. Development 1995;121:2419-2428.
30. Kenny AJ, O'Hare MJ, Gusterson BA. Cell-surface peptidases as modulators of growth and differentiation. Lancet 1989;2:785-787. (Pubitemid 19234819)
31. Reversi A, Cassoni P, Chini B. Oxytocin receptor signaling in myoepithelial and cancer cells. J Mammary Gland Biol Neoplasia 2005;10:221-229.
32. Galy A, Morel F, Hill B et al. Hematopoietic progenitor cells of lymphocytes and dendritic cells. J Immunother 1998;21:132-141. (Pubitemid 28141718)
33. Buhring HJ, Battula VL, Treml S et al. Novel markers for the prospective isolation of human MSC. Ann N Y Acad Sci 2007;1106:262-271. (Pubitemid 47443036)
34. Stingl J, Raouf A, Emerman JT et al. Epithelial progenitors in the normal human mammary gland. J Mammary Gland Biol Neoplasia 2005;10:49-59. (Pubitemid 40724022)
35. Bachelard-Cascales E, Chapellier M, Delay E et al. The CD10 enzyme is a key player to identify and regulate human mammary stem cells. Stem Cells 2010;28:1081-1088.
36. Sapino A, Macri L, Tonda L et al. Oxytocin enhances myoepithelial cell differentiation and proliferation in the mouse mammary gland. Endocrinology 1993;133:838-842. (Pubitemid 23238900)
37. Greaves MF, Brown G, Rapson NT et al. Antisera to acute lymphoblastic leukemia cells. Clin Immunol Immunopathol 1975;4:67-84.
38. Pesando JM, Ritz J, Lazarus H et al. Leukemia-associated antigens in ALL. Blood 1979;54:1240-1248. (Pubitemid 10212765)
39. Choi WW, Weisenburger DD, Greiner TC et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494-5502.
40. Wood BL, Arroz M, Barnett D et al. 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: Optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin Cytom 2007;72(suppl 1):S14-S22. (Pubitemid 350194344)
41. Dakka N, Bellaoui H, Bouzid N et al. CD10 AND CD34 expression in childhood acute lymphoblastic leukemia in Morocco: Clinical relevance and outcome. Pediatr Hematol Oncol 2009;26:216-231.
42. Borowitz MJ, Devidas M, Hunger SP et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children's Oncology Group study. Blood 2008;111:5477-5485.
43. Pilkington GR, Pallesen G. Phenotypic characterization of non-haemopoietic small cell tumours of childhood with monoclonal antibodies to leucocytes, epithelial cells and cytoskeletal proteins. Histopathology 1989;14:347-357. (Pubitemid 19129376)
44. Carrel S, Zografos L, Schreyer M et al. Expression of CALLA/CD10 on human melanoma cells. Melanoma Res 1993;3:319-323. (Pubitemid 23329693)
45. Chu P, Arber DA. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol 2000;113:374-382. (Pubitemid 30217385)
46. Cohen AJ, Bunn PA, Franklin W et al. Neutral endopeptidase: Variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux. Cancer Res 1996;56:831-839. (Pubitemid 26055474)
47. Yada K, Kashima K, Daa T et al. Expression of CD10 in basal cell carcinoma. Am J Dermatopathol 2004;26:463-471. (Pubitemid 40082510)
48. Notohara K, Hamazaki S, Tsukayama C et al. Solid-pseudopapillary tumor of the pancreas: Immunohistochemical localization of neuroendocrine markers and CD10. Am J Surg Pathol 2000;24:1361-1371.
49. Borscheri N, Roessner A, Rocken C. Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas. Am J Surg Pathol 2001;25:1297-1303. (Pubitemid 32917124)
50. Makretsov NA, Hayes M, Carter BA et al. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod Pathol 2007;20:84-89. (Pubitemid 44967953)
51. Huang WB, Zhou XJ, Chen JY et al. CD10-positive stromal cells in gastric carcinoma: Correlation with invasion and metastasis. Jpn J Clin Oncol 2005;35:245-250.
52. Terauchi M, Kajiyama H, Shibata K et al. Anti-progressive effect of neutral endopeptidase 24.11 (NEP/CD10) on cervical carcinoma in vitro and in vivo. Oncology 2005;69:52-62. (Pubitemid 41207058)
53. Bircan S, Candir O, Kapucuoglu N et al. CD10 expression in urothelial bladder carcinomas: A pilot study. Urol Int 2006;77:107-113. (Pubitemid 44195767)
54. Karabork A, Kaygusuz G, Ekinci C. The best immunohistochemical panel for differentiating hepatocellular carcinoma from metastatic adenocarcinoma. Pathol Res Pract 2010;206:572-577.
55. Oliva E. CD10 expression in the female genital tract: Does it have useful diagnostic applications? Adv. Anat Pathol 2004;11:310-315.
56. Pires FR, Azevedo RS, Ficarra G et al. Metastatic renal cell carcinoma to the oral cavity and clear cell mucoepidermoid carcinoma: Comparative clinicopathologic and immunohistochemical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;109:e22-e27.
57. Rivera AL, Takei H, Zhai J et al. Useful immunohistochemical markers in differentiating hemangioblastoma versus metastatic renal cell carcinoma. Neuropathology 2010;30:580-585.
58. Abdou AG. CD10 expression in tumour and stromal cells of bladder carcinoma: An association with bilharziasis. APMIS 2007;115:1206-1218. (Pubitemid 350293947)
59. Tokuhara T, Adachi M, Hashida H et al. Neutral endopeptidase/CD10 and aminopeptidase N/CD13 gene expression as a prognostic factor in non-small cell lung cancer. Jpn J Thorac Cardiovasc Surg 2001;49:489-496.
60. Deschamps L, Handra-Luca A, O'Toole D et al. CD10 expression in pancreatic endocrine tumors: Correlation with prognostic factors and survival. Hum Pathol 2006;37:802-808. (Pubitemid 43902955)
61. Fujita S, Taniguchi H, Yao T et al. Multi-institutional study of risk factors of liver metastasis from colorectal cancer: Correlation with CD10 expression. Int J Colorectal Dis 2010;25:681-686.
62. Piattelli A, Fioroni M, Iezzi G et al. CD10 expression in stromal cells of oral cavity squamous cell carcinoma: A clinic and pathologic correlation. Oral Dis 2006;12:301-304. (Pubitemid 43736419)
63. Langner C, Ratschek M, Rehak P et al. CD10 is a diagnostic and prognostic marker in renal malignancies. Histopathology 2004;45:460-467. (Pubitemid 39524320)
64. Smollich M, Gotte M, Yip GW et al. On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer. Breast Cancer Res Treat 2007;106:361-369. (Pubitemid 350029691)
65. Lerwill MF. Current practical applications of diagnostic immunohistochemistry in breast pathology. Am J Surg Pathol 2004;28:1076-1091. (Pubitemid 38971434)
66. Hu M, Yao J, Carroll DK et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008;13:394-406. (Pubitemid 351609443)
67. Fleischmann A, Schlomm T, Huland H et al. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients. Clin Cancer Res 2008;14:7838-7842.
68. Osman I, Yee H, Taneja SS et al. Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin Cancer Res 2004;10(12 part 1):4096-4100. (Pubitemid 38812488)
69. Erhuma M, Kobel M, Mustafa T et al. Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues. Int J Cancer 2007;120:2393-2400. (Pubitemid 46642126)
70. Kuniyasu H, Luo Y, Fujii K et al. CD10 enhances metastasis of colorectal cancer by abrogating the anti-tumoural effect of methionine-enkephalin in the liver. Gut 2010;59:348-356.
71. Horejsi V, Drbal K, Cebecauer M et al. GPI-microdomains: A role in signalling via immunoreceptors. Immunol Today 1999;20:356-361. (Pubitemid 29356429)
72. Ganju RK, Shpektor RG, Brenner DG et al. CD10/neutral endopeptidase 24.11 is phosphorylated by casein kinase II and coassociates with other phosphoproteins including the lyn src-related kinase. Blood 1996;88:4159-4165. (Pubitemid 26399161)
73. Zheng R, Horiguchi A, Iida K et al. Neutral endopeptidase is a myristoylated protein. Mol Cell Biochem 2010;335:173-180.
74. Iwase A, Shen R, Navarro D et al. Direct binding of neutral endopeptidase 24.11 to ezrin/radixin/moesin (ERM) proteins competes with the interaction of CD44 with ERM proteins. J Biol Chem 2004;279:11898-11905. (Pubitemid 38401695)